Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials

IMPORTANCE: Phase 2 trials and early efficacy end points play a crucial role in informing decisions about whether to continue to phase 3 trials. Conventional end points, such as objective response rate (ORR) and progression-free survival (PFS), have demonstrated inconsistent associations with overal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chen, Wang, Meihua, Wu, Cai, Zhou, Heng, Chen, Cong, Diede, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164100/
https://www.ncbi.nlm.nih.gov/pubmed/34047794
http://dx.doi.org/10.1001/jamanetworkopen.2021.8175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164100/
https://www.ncbi.nlm.nih.gov/pubmed/34047794
http://dx.doi.org/10.1001/jamanetworkopen.2021.8175

Ejemplares similares